$mdna We know how $nktr and thor did in their ph1-2 trials. They both showed NO monotheraphy efficacy. That's why they are in phase 3 combo trials with checkpoint inhibitors. Take a look at Synthekine presentation recently. They do a good job of talking about the underwhelming results of $nktr and thor. In biotech being first is important, but it's not the ONLY thing that matters. $MDNA just started it's phase 1 trial... based on animal data including non-human primates, they appear to have best-in-class. We need to see phase1 trials to confirm that. It's important to note in the IL-2 space, as stated by $nktr and thor as well, the animal models have been directionally accurate in terms of safety, efficacy, PK charactersitics etc. If you look at stuff they put out, that's what they say. You never know with animal studies, but specifically for IL-2 space, animal models seem to be very accurate. Go to medicenna's and synthekine materials (both are using tech from chris garcia's lab) and both mdna and synthenkine show their animal models are way superior to $nktr and thor. Again, we need confirmation via ph1 results for $mdna. Il-2 targeted market is HUGE. There is room for multiple players not just one or two, esp if you have best-in-class. There are many examples in biotech where there are multiple players competing... checkpoint inhibitors case in point. Cancer immunotherapy is huge and is going to continue to get huger. "The global Cancer Immunotherapy Mkt size is expected to reach USD 168.48 billion in 2028," There is space for
$MDNA to be a multi-billion dollar company, when it proves out that it has monotherapy efficacy, combo with checkpoint efficacy, and is best-in-class. December results in my mind are the most important even though it is just safety and pk results readout. If safety and PK shows what they showed in animal models, we can assign high probability that efficacy is going to shine through in results in 2022. $MDNA is way too cheap here at $160 mm market cap. that's the other thing... good results, you easily have 10x+ potential given how cheap it is compared to every single iL-2 player out there. It is by far the cheapest, bar none. which makes no sense to me whatsoever